- Report
- June 2025
- 274 Pages
Global
From €4847EUR$5,550USD£4,211GBP
- Report
- December 2024
- 150 Pages
Global
From €5196EUR$5,950USD£4,514GBP
- Report
- August 2025
- 180 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 187 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- April 2025
- 175 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- September 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- September 2025
- 409 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- February 2025
- 148 Pages
Global
From €2619EUR$2,999USD£2,275GBP
- Report
- May 2025
- 131 Pages
Global
From €4148EUR$4,750USD£3,604GBP
- Report
- September 2025
- 300 Pages
Global
From €3489EUR$3,995USD£3,031GBP
- Report
- October 2024
- 750 Pages
Global
From €3489EUR$3,995USD£3,031GBP
- Report
- November 2024
- 478 Pages
Global
From €4323EUR$4,950USD£3,755GBP
- Report
- August 2025
- 155 Pages
Global
From €2314EUR$2,650USD£2,010GBP
- Report
- March 2025
- 451 Pages
Global
From €4323EUR$4,950USD£3,755GBP
- Report
- May 2025
- 272 Pages
Global
From €4061EUR$4,650USD£3,528GBP
- Report
- April 2025
- 200 Pages
Global
From €5196EUR$5,950USD£4,514GBP
- Report
- December 2024
- 150 Pages
Global
From €5196EUR$5,950USD£4,514GBP
- Report
- July 2025
- 175 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- August 2025
- 185 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 197 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP

The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them.
The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives.
Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more